1. Home
  2. XBIT vs EARN Comparison

XBIT vs EARN Comparison

Compare XBIT & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.32

Market Cap

69.8M

Sector

Health Care

ML Signal

N/A

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.42

Market Cap

169.8M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
EARN
Founded
2005
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
169.8M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
XBIT
EARN
Price
$2.32
$4.42
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
23.9K
409.3K
Earning Date
05-08-2026
06-16-2026
Dividend Yield
N/A
20.51%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.69
Revenue Next Year
N/A
$19.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$4.25
52 Week High
$3.61
$5.89

Technical Indicators

Market Signals
Indicator
XBIT
EARN
Relative Strength Index (RSI) 50.02 52.49
Support Level $2.30 $4.29
Resistance Level $2.32 $4.48
Average True Range (ATR) 0.07 0.07
MACD 0.00 0.01
Stochastic Oscillator 29.17 78.26

Price Performance

Historical Comparison
XBIT
EARN

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

Share on Social Networks: